Connect public, paid and private patent data with Google Patents Public Datasets

Trazodone Composition for Once a Day Administration

Download PDF

Info

Publication number
US20110015205A1
US20110015205A1 US12892466 US89246610A US20110015205A1 US 20110015205 A1 US20110015205 A1 US 20110015205A1 US 12892466 US12892466 US 12892466 US 89246610 A US89246610 A US 89246610A US 20110015205 A1 US20110015205 A1 US 20110015205A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
trazodone
release
composition
example
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12892466
Inventor
Sonia Gervais
Damon Smith
Miloud Rahmouni
Pauline Contamin
Rachid Ouzerourou
My Linh Ma
Angela Ferrada
Fouzia Soulhi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Pharma Inc
Original Assignee
Labopharm (Barbados) Ltd
Paladin Labs Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.

Description

    RELATED APPLICATIONS
  • [0001]
    This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/715,162, filed Sep. 9, 2005, the entire disclosure of which is incorporated by reference herein.
  • FIELD OF THE INVENTION
  • [0002]
    The present invention relates to the anti-depressant trazodone and in particular to a once a day formulation of trazodone, and to its use for treating depression and certain sleep disorders.
  • BACKGROUND
  • [0003]
    Trazodone is a serotonin-2 receptor antagonist/reuptake inhibitor that also decreases extracellular gamma-amino-butyric acid (GABA) levels in the cerebral cortex, through the blockade of 5-hydroxytryptamine2A (5-HT2A) receptors. This decrease is accompanied by an increase in (5-HT) release. Higher doses of trazodone inhibit 5-HT transport and this uptake inhibition results in a further increase in 5-HT levels. It is contemplated that this double mechanism may be responsible for the anti-depressant properties of trazodone. Moreover, the interaction between the GABAergic and serotoninergic systems may explain its sedative, anxiolytic properties.
  • [0004]
    Trazodone is therefore a psychoactive compound with sedative and anti-depressant properties. It is rapidly absorbed from the upper gastro-intestinal tract and is extensively metabolized after oral administration. It is normally used to relieve symptoms of depression such as feelings of sadness, worthlessness, or guilt; loss of interest in daily activities; changes in appetite; tiredness; thoughts of death or suicide; and insomnia. Trazodone may also be used for other purposes, and details thereof are well documented in the art.
  • [0005]
    Trazodone is a triazolopyridine derivative of the formula
  • [0000]
  • [0000]
    which is shown in its normally used hydrochloride form. Preparation of this compound was first disclosed in U.S. Pat. No. 3,381,009 which issued in 1968 to G. Palazzo et al.
  • [0006]
    The solubility of trazodone is pH dependent and has a pKa of 6.74 in water. As a result, trazodone is highly soluble in acid media (as found in the stomach and upper intestines) i.e., when below its pKa. In contrast, when above its pKa, its solubility is very low, for example, in the neutral and basic conditions of the lower intestine. Such insolubility obviously has an effect on its dissolution and, therefore, on the availability of the drug for absorption in the lower intestine. These features would be expected to hinder the development of long acting (for example, greater than 8 hours) forms of trazodone, which require substantially uniform absorption along the length of the gastrointestinal tract, in particular, absorption during passage through both the upper and lower intestinal tracts.
  • [0007]
    As with many drugs, trazodone is normally prescribed as an immediate release form for use two times (BID) or three times (TID) a day, with all the inconveniences and disadvantages that this involves. For example, BID or TID dosing with immediate release forms of trazodone results in concentrations of the drug in the blood that do not remain within the so-called therapeutic window and which, therefore, can be associated with higher risks of dose related adverse effects when reaching high levels, or lower degree of efficacy when reaching low levels. In addition, multiple daily doses may lead to several periods of drowsiness throughout the day associated with peak trazodone concentrations occurring immediately after administration.
  • [0008]
    As a result, there is a need for a once a day (OAD) formulation of trazodone that from a single tablet rapidly achieves and maintains stable, effective concentrations over 24 hours and more and that is pH-independent in its release profile so that trazodone may be uniformly absorbed along substantially the entirety of the upper and lower gastrointestinal tract, thereby reducing the frequency and severity of side effects such as drowsiness during the day.
  • SUMMARY OF THE INVENTION
  • [0009]
    The invention provides a sustained release pharmaceutical composition for once a day oral administration or trazodone or a derivative thereof. The composition comprises from about 15% to about 60% by weight trazodone or a derivative thereof, and from about 15% to about 85% by weight percent of a controlled release excipient. The controlled release excipient, when orally administered to a mammal, for example, a person, permits the trazodone or derivative thereof to achieve an effective plasma concentration from at least about 1 hour to about 24 hours after initial administration. Under certain circumstances, the controlled release excipient provides a substantially pH independent controlled release of the trazodone or derivative thereof so that the trazodone or the trazodone derivative can be absorbed during passage through both the upper and lower gastrointestinal tracts.
  • [0010]
    The sustained release formulations provide plasma concentrations of trazodone or trazodone derivatives for at least 24 hours that are effective at treating, i.e., ameliorating, one or more of the symptoms of depression. In another embodiment, the sustained release formulations provide effective amounts of trazodone or a trazodone derivative for treating sleeping disorders, for example, improving sleep architecture.
  • [0011]
    The sustained release excipient can provide a therapeutically effective plasma trazodone or trazodone derivative concentration that remains substantially constant between about 50 ng/mL and about 3000 ng/mL for a period that extends about one hour after ingestion to at least about 24 hours. Plasma concentrations typically are dependent on the dose administered. For example, in one embodiment, a sustained release pharmaceutical composition contemplated herein comprises 150 mg of trazodone hydrochloride. Such a formulation provides an effective plasma trazodone concentration from at least about 1 hour to about 24 hours after initial administration of between about 150 ng/mL and about 500 ng/mL. In another embodiment, the sustained release pharmaceutical composition comprises 300 mg of trazodone hydrochloride. Such a formulation provides an effective plasma trazodone concentration from at least about 1 hour to about 24 hours after initial administration of between about 300 ng/mL and about 1000 ng/mL.
  • [0012]
    In certain embodiments, the sustained release pharmaceutical composition comprises from about 15% to about 60% by weight trazodone or a derivative thereof and from about 15% to about 85% by weight percent of controlled release excipient. In other embodiments, the composition comprises from about 20% to about 50% weight percent trazodone and from about 20% to about 50% weight percent of controlled release excipient. For example, the composition may comprise about 35% to about 50% weight percent trazodone and from about 15% to about 50% weight percent of controlled release excipient.
  • [0013]
    It is contemplated that a number of different excipients may be useful in the practice of the invention. In one embodiment, the controlled release excipient comprises cross-linked high amylose starch. In certain embodiments, the cross-linked high amylose starch is cross linked with phosphorus oxychloride and/or comprises hydroxypropyl side chains. In certain embodiments, the cross-linked high amylose starch comprises between about 65% and 75% by weight amylose and is cross-linked with phosphorus oxychloride. One preferred cross-linked high amylose starch useful in the practice of the invention is known as CONTRAMID® cross-linked, high amylose starch, available commercially from Labopharm, Inc., Laval, Canada.
  • [0014]
    In addition, the sustained release pharmaceutical composition may optionally include more or more pharmaceutical additives. Exemplary pharmaceutical additives include binding agents (for example, hydroxypropylmethylcellulose), solubilizing agents (for example, povidone or cetylpyridinium chloride), acidifying agents (for example, alginic acid), pore forming agents (for example, sucrose), lubricants (for example, sodium stearyl fumarate), and glidants (for example, colloidal silicon dioxide).
  • [0015]
    In one embodiment, the invention provides a sustained release pharmaceutical composition comprising about 20% to about 50% by weight trazodone hydrochloride, about 20% to about 50% by weight cross-linked high amylose starch, about 10% to about 20% by weight hydroxypropylmethylcellulose, about 0% to about 5% by weight cetylpyridinium chloride, about 0% to about 20% by weight alginic acid, about 1% to about 5% by weight percent sodium stearyl fumarate, and up to about 1% by weight percent colloidal silicon dioxide.
  • [0016]
    The sustained release pharmaceutical composition can be formulated into a variety of shapes and forms such as tablets and caplets suitable for oral administration. In one embodiment, the invention provides a caplet comprising 300 mg of trazodone. Such a caplet can be adapted for administration before bedtime. Such a formulation rapidly induces somnolence after oral administration but yet provides substantially no drowsiness in a patient about 8 hours after oral administration as compared to repeat administration of an immediate release trazodone composition.
  • [0017]
    The invention provides for unit dose sustained release pharmaceutical composition for once a day oral administration of 300 mg trazodone hydrochloride is comprising about 20% to about 40% by weight of a controlled release excipient, wherein when ingested orally, the composition provides area under the concentration-time curve substantially equivalent to the commercially available daily dose of three 100 mg strength trazodone hydrochloride tablets, wherein the three tablets are administered over 24 hours. Also provided herein is a unit dose sustained release pharmaceutical composition for once a day oral administration of 150 mg trazodone hydrochloride comprising about 30% to about 50% by weight of a controlled release excipient, wherein when ingested orally, the composition provides area under the concentration-time curve substantially equivalent to the commercially available daily dose of three, 50 mg strength trazodone hydrochloride tablets, wherein the three tablets are administered over 24 hours.
  • [0018]
    In addition, the invention provides a method of treating depression by administering once a day to a person in need of an anti-depressant, one of the sustained release pharmaceutical compositions described above. The composition can be administered before bedtime.
  • [0019]
    In addition, the invention provides a method of improving the sleep architecture in a person in need of treatment thereof, the method comprises administering once a day to such a person, one of the sustained release pharmaceutical compositions described above. The composition preferably is administered before bedtime.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0020]
    The invention is illustrated but is not limited by the annexed drawings, in which
  • [0021]
    FIG. 1 is a graph illustrating the in vitro dissolution profile of a first 300 mg trazodone OAD formulation;
  • [0022]
    FIG. 2 is graph that illustrates the plasma trazodone concentration derived from a single tablet of the first 300 mg trazodone OAD formulation as a function of time when administered to a human;
  • [0023]
    FIG. 3 is a graph illustrating the in vitro dissolution profile of a second 300 mg trazodone OAD formulation;
  • [0024]
    FIG. 4 is graph that illustrates the plasma trazodone concentration derived from a single tablet of a second 300 mg trazodone OAD formulation as a function of time when administered to a human;
  • [0025]
    FIG. 5 is a graph illustrating the in vitro dissolution profile of a 150 mg trazodone OAD formulation; and
  • [0026]
    FIG. 6 is graph that illustrates the plasma trazodone concentration derived from a single tablet of a 150 mg trazodone OAD formulation as a function of time when administered to a human.
  • DETAILED DESCRIPTION
  • [0027]
    The invention is based, in part, upon the discovery that it is possible to formulate a once a day formulation of trazodone or a trazodone derivative that provides a plasma concentration of the active ingredient that is essentially stable between one hour and twenty four hours that is effective in the treatment of, i.e., ameliorating one or more of the systems of depression. This discovery was surprising because, even though the solubility of trazodone is pH dependent, and decreases rapidly at the higher pH found in the lower gastrointestinal tract, it has been found that it is possible to provide therapeutic, stable and/or effective concentrations of trazodone in the blood stream for at least 24 hours irrespective of changes in pH through the upper and lower intestinal tracts.
  • [0028]
    Accordingly, the invention provides a sustained release pharmaceutical composition for once a day oral administration or trazodone or a derivative thereof. The composition comprises from about 15% to about 60% by weight trazodone or a derivative thereof, and from about 15% to about 85% by weight percent of a controlled release excipient. The controlled release excipient, when orally administered to a mammal, for example, a person, permits the trazodone or derivative thereof to achieve and/or maintain an effective plasma concentration, for example, a therapeutically effective plasma concentration from at least about 1 hour to about 24 hours after initial administration for treating depression.
  • [0029]
    In addition, it is possible to use the same or similar formulations for treating sleep disorders, for example, improving sleep architecture. The controlled release excipient, when orally administered to a mammal, for example, a person, permits the trazodone or derivative thereof to achieve an effective plasma concentration for treating a sleep disorder. Such a formulation rapidly (for example, within 1 hour) induces somnolence after oral administration but yet provides substantially no drowsiness in a patient about 8 hours after oral administration, as compared to repeat administration of an immediate release trazodone composition.
  • [0030]
    The formulations described herein provide a rapid rise in plasma concentrations of the active ingredient, which thereafter remain relatively and substantially stable for at least 24 hours or more. The plasma concentration between 1 hour and 24 hours remains within about 45% of the mean plasma concentration, more preferably between about 30% of the mean plasma concentration, and most preferably between about 15% of the mean plasma concentration. In certain formulations, after an initial rapid release of trazodone or the trazodone derivative within an hour of ingestion the trazodone or the trazodone derivative is released in vivo with approximately zero order kinetics for at least about 24 hours, leading to plateau plasma concentrations. In these formulations, the effective plasma concentration of the trazodone formulation remains generally constant about 1 hour after ingestion, and can be between about 60 ng/mL and about 3000 ng/mL, between about 150 ng/mL and 1500 ng/mL, between about 600 ng/mL and 1300 ng/mL, between about 500 ng/mL and 1200 ng/mL, or between about 300 ng/mL and 650 ng/mL at least up to about 24 hours after oral administration.
  • [0031]
    Formulations contemplated herein may reach steady-state, for example, on-average, within a normal population, after about the fourth administration. The peak-to-trough ratio produced by such formulations at steady-state may be about 60% to about 100%.
  • [0032]
    The sustained release trazodone formulations contemplated herein may have effective plasma concentrations that are for example bioequivalent with respect to the AUC (area under the curve) of a immediate release formulation that is administered, for example, two or three times day. The AUC is a mathematical calculation to evaluate the body's total exposure over time to a given drug and refers to the area under the curve in a plot of concentration of drug against time. AUC's are used as a guide for dosing schedules and to compare the bioavailability of different drug formulations in the body.
  • [0033]
    The formulations described herein are particularly useful in the delivery of trazodone and trazodone derivatives. Derivatives include pharmaceutically acceptable prodrugs, metabolites, salts and esters, or the like of trazodone. For example, the term “pharmaceutically-acceptable salts” is art-recognized and refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds, including, for example, those contained in compositions of the present invention. In a preferred embodiment, the active ingredient in the formulation is trazodone hydrochloride.
  • [0034]
    A composition according to the invention may include trazodone or its derivatives and a controlled release excipient. In some embodiments, compositions disclosed herein include more than about 15% trazodone or its derivatives by weight, for example between about 15% and about 60%, or between about 20% and about 60%, or between about 20% and about 55% by weight. In other embodiments, compositions contemplated herein may include more than about 15% weight controlled release excipient, for example, between about, 15% and about 85%, or about 20% and about 85%, or about 20% and about 60%, or about 20% and about 50%, or about 30% to about 50% by weight. The composition according to the invention preferably comprises from about 20% to about 50% by weight, more preferably from about 25% to about 50% trazodone or trazodone derivative, and from about 20% to 50% by weight, more preferably from about 25% to about 50% by weight of controlled release excipient. In a particular embodiment, this invention is directed to a composition comprising about 25% to about 50% trazodone hydrochloride by weight and about 30% to about 50% cross-linked high amylose starch, such as disclosed herein.
  • [0035]
    A practical example of a sustained release pharmaceutical composition according to the invention, is one containing 150 mg of trazodone hydrochloride. This formulation can provide an effective plasma concentration preferably in the range of about 150 ng/mL to 500 ng/mL between about 1 and 24 hours after the first administration. Another practical example is one wherein the composition comprises 300 mg of trazodone hydrochloride. This formulation can provide a plasma trazodone concentration preferably in the range of about 300 ng/mL to 1000 ng/mL. Of course, other compositions according to the invention may be prepared with different amounts of trazodone or its derivatives with correspondingly varying plasma concentrations that can be for example, between about 50 ng/mL and about 3000 ng/mL.
  • [0036]
    Controlled release excipients contemplated herein may vary to a large extent as is well known to one skilled in the art, provided that a formulation including an excipient has the disclosed therapeutic action and/or provides a pH independent delivery of trazodone or a trazodone derivative. Controlled release excipients may include cross-linked starches, hydrogels, celluloses, and/or polymers, and other controlled release excipients known to those skilled in the art.
  • [0037]
    In one embodiment, the controlled release excipient preferably comprises a cross-linked high amylose starch, for example, where the cross-linked high amylose starch is cross-linked with phosphorus oxychloride and/or comprises hydroxypropyl side chains. In certain embodiments, the cross-linked high amylose starch comprises between about 65% and 75% by weight amylose and is cross-linked with phosphorus oxychloride. A suitable excipient has been developed by and is available commercially from Labopharm, Inc., Laval, Canada, under the trademark CONTRAMID®. The synthesis of the CONTRAMID® excipient is described, for example, in U.S. Pat. No. 6,607,748, hereby incorporated by reference in its entirety for all purposes. Compositions contemplated herein may include cross-linked high amylose starch together with one or more additional controlled release excipients.
  • [0038]
    Cross-linking of starch represents a powerful method for modifying starch. Usually, starch granules are cross-linked to increase resistance of the paste to shear or heat. Such chemically cross-linked starches provide a desirable smooth texture and possess viscosity stability throughout processing operations and normal shelf life. In some embodiments, cross-linked high amylose starch as contemplated herein may be gelatinized after cross-linking. In a preferred embodiment, cross-linking high amylose starch may include additional chemical modification (e.g., hydroxypropylation) prior to gelatinization.
  • [0039]
    The cross-linking of high amylose starch may be realized according to procedures described in the art. For example, cross-linking of amylose can be carried out in the manner described in Mateescu [BIOCHEMIE 60: 535-537 (1978)] by reacting amylose with epichlorohydrin in an alkaline medium. In the same manner, starch can also be cross-linked with a reagent selected from the group consisting of epichlorohydrin, adipic acid anhydride, sodium trimetaphosphate and phosphorous oxychloride or other cross-linking agents including, but not limited to, 2,3-dibromopropanol, linear mixed anhydrides of acetic and di- or tribasic carboxylic acids, vinyl sulfone, diepoxides, cyanuric chloride, hexahydro-1,3,5-trisacryloyl-s-triazine, hexamethylene diisocyanate, toluene 2,4-diisocyanate, N,N-methylenebisacrylamide, N,N′-bis (hydroxymethyl) ethyleneurea, mixed carbonic-carboxylic acid anhydrides, imidazolides of carbonic and polybasic carboxylic acids, imidazolium salts of polybasic carboxylic acids, and guanidine derivatives of polycarboxylic acids. The reaction conditions employed will vary with the type and amount of the cross-linking agent that is used, as well as the base concentration, amount and type of starch.
  • [0040]
    It is contemplated that starches containing more than about 40% w/w amylose can be used to form cross-linked high amylose starch, e.g., pea and wrinkled pea starch, bean starch, hybrids or genetically modified tapioca or potato starch, or any other root, tuber or cereal starch. Preferably, high amylose starch containing about 70% w/w amylose is used as the base material. For example, high amylose starch, Cerestar AmyloGel 03003 (Cerestar U.S.A. Inc.), may be used.
  • [0041]
    It has been discovered that by combining trazodone or a trazodone derivative with a controlled release excipient, for example, cross-linked high amylase starch (for example, CONTRAMID® cross-linked high amylose starch), trazodone, which is pH sensitive with a pKa of about 6.74 can be released and absorbed not only in the upper gastrointestinal tract where the pH is below the pKa of trazodone (where trazodone is soluble) but also in the lower gastrointestinal tract where the pH is above the pKa of trazodone (where trazodone is poorly soluble) thereby maintaining stable plasma concentrations in the blood throughout gastrointestinal transit. To this day, to our knowledge, no once a day formulation including a pH dependent active agent has been suggested or designed for a composition that has the pharmacokinetic profile described herein.
  • [0042]
    The pharmaceutical composition according to the invention may also comprise pharmaceutically acceptable additives. Such additives can include, for example, sugars, such as lactose, glucose and sucrose; other starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; and other non-toxic compatible substances employed in pharmaceutical formulations. Such additives may also include colorants.
  • [0043]
    For example, the compositions disclosed herein may include any one of a mixture of a binding agent, a solubilizing agent, an acidifying agent, a pore forming agent, a lubricant, a glidant, and the like, as is well known to those skilled in the art. Preferred pharmaceutical additives that are used in providing a composition according to the invention may include, for example, binding agents that include, for example, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, dicalcium phosphate, calcium phosphate, microcrystalline cellulose, or the like, solubilizing agents that include, for example, povidone, cetylpyridinium chloride, or the like, acidifying agents that include, for example, alginic acid, citric acid, succinic acid, bile acid or the like, pore forming agents, that include, for example, sucrose, lactose, mannitol or the like, lubricants that include, for example, sodium stearyl fumarate, magnesium stearate, calcium stearate, stearic acid, hydrogentated vegetable oils or the like and/or glidants that include, for example, colloidal silicon dioxide, talc or the like. Other additives that are well known to those skilled in the art may of course be included in the composition according to the invention without departing from the scope and spirit of the present invention.
  • [0044]
    For example, the composition according to the invention may comprise about 20 to 50 weight percent trazodone hydrochloride, about 20 to 50 weight percent cross-linked high amylase starch (for example, CONTRAMID® cross-linked high amylose starch), about 10 to 25 weight percent hydroxypropylmethylcellulose, about 0 to 10 weight percent cetylpyridinium chloride, about 0 to 20 weight percent alginic acid, about 1 to 5 weight percent sodium stearyl fumarate, and up to about 1 weight percent colloidal silicon dioxide.
  • [0045]
    The composition according to the invention is normally prepared in the form of a tablet. Although the tablet can adopt a wide variety of shapes as is well known to those skilled in the art, the preferred shape is a caplet. Such caplets may be formed using, for example, upper and lower punches as is known in the art. In some embodiments, tablets may include a coat, such as, for example, a coating with a colorant. Suitable coatings include, for example, aqueous film coating polymers such as polyvinyl alcohol, talc, macrogol and the like, and mixtures thereof. Suitable colorants include, for example, iron oxides, lakes, natural colorants and other colorants known to those skilled in the art.
  • [0046]
    In an exemplary formulation protocol for producing a 5 kg batch of an exemplary sustained release formulation, CONTRAMID® excipient, hydroxypropylmethyl cellulose, trazodone HCl and sodium stearyl fumarate are individually weighed and sifted through a 30 mesh filter. Colloidal silicon dioxide is weighed and pre-blended with CONTRAMID®, sifted through a 30 mesh filter, and blended for 10-30 seconds, for example, 15 seconds to produce a pre-blend. Hydroxypropylmethylcellulose, trazodone and the Contramid®-collodial silicon dioxide pre-blend, are combined and blended for 5-10 minutes, for example, 7 minutes, to produce a bulk blend. A small portion of the resulting bulk blend is combined with the sodium stearyl fumarate and blended for 20-60 seconds, for example, 30 seconds. The resulting sodium stearyl fumarate blend is combined with the residual bulk blend, and the resulting mixture blended for about 2-6 minutes, for example, 4 minutes. The final blend is compressed into tablets using a compression pressure of 27 kN. Caplets are formed using a caplet standard concave punch.
  • [0047]
    A dosage for once a day administration may be 25 mg to 600 mg of trazodone or a trazodone derivative. Typical doses for once a day administration include 150 mg or 300 mg of trazodone or a trazodone derivative, although this amount may vary to a large extent depending on required needs, and the specific requirements of the treating physician. For example, the dosage of any compositions of the present invention will vary depending on the symptoms, age and body weight of the patient, the nature and severity of the disorder to be treated or prevented, the route of administration, and the form of the subject composition. Dosages for the compositions of the present invention may be readily determined by techniques known to those of skill in the art or as taught herein. The precise time of administration and amount of any particular subject composition that will yield the most effective treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a subject composition, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage and type of medication), route of administration, and the like. The guidelines presented herein may be used to optimize the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the subject and adjusting the dosage and/or timing.
  • [0048]
    The resulting formulations have in vitro profiles, preferably, as described in Examples 1 and 3, hereinbelow. The in vitro release profiles were measured as follows. Briefly, the release rates were determined using a U.S.P. paddle method (apparatus type II as described in U.S.P. XXVI) at 150 revolutions per minute, at 37±0.5° C., in 900 mL of hydrochloride/sodium chloride pH 1.2 solution (acid stage) followed after one hour by 900 mL of sodium phosphate monobasic buffer pH 6.0 (buffer stage). In some embodiments; formulations may have release kinetics, whereby, when tested by the foregoing method, not more than about 30% of the active ingredient is released by 1 hour after initiation of the experiment, about 35% to 60% of the active ingredient is released by 6 hours, not more than about 80% of the active ingredient is released by 12 hours, and/or not less than about 80% of the active ingredient is released by 24 hours.
  • [0049]
    The compositions described herein are particularly useful in treating depression, disorders associated with depression, and sleep disorders. According, a mammal suffering from depression can be administered once a day (for example, at bedtime) with a trazodone formulation as defined above. A mammal to be treated by the subject method may mean either a human or non-human animal.
  • [0050]
    The compositions described herein may also be useful in treating patients that have difficulty sleeping and/or have disrupted sleep architecture, i.e., disrupted non-REM/REM stage and cycle infrastructure of sleep. In some embodiments, formulations disclosed herein release a therapeutically effective portion of trazodone within one hour after oral administration and thus rapidly induce somnolence but yet provide substantially no drowsiness in a patient about 8 hours after oral administration as compared to repeat administration of an immediate release trazodone composition. Accordingly, such formulations reduce undesirable drowsiness in waking hours or in the day time.
  • [0051]
    The invention will now be illustrated by means of the following examples which are given for the purpose of illustration only and without any intention to limit the scope of the present invention.
  • EXAMPLES Example 1
  • [0052]
    A first sustained release 300 mg trazodone containing formulation (denoted Formulation 1) was prepared having the composition set forth in TABLE 1.
  • [0000]
    TABLE 1
    Formulation 1
    Tablet Tablet
    Ingredients (mg) %
    CONTRAMID ® excipient 200 32.7
    Trazodone HCl 300 49.0
    Hydroxylpropylmethyl cellulose K100M 100 16.3
    Colloidal silicon dioxide 3 0.5
    Sodium stearyl fumarate 9 1.5
    Total 612 100
  • [0053]
    The in vitro release kinetics of this formulation were measured using the U.S.P. paddle method (apparatus type II as described in U.S.P. XXVI) at 150 revolutions per minute, at 37±0.5° C., in 900 mL of hydrochloride/sodium chloride pH 1.2 solution (acid stage) followed after one hour by 900 mL of sodium phosphate monobasic buffer pH 6.0 (buffer stage). This formulation, when tested using the foregoing method, had an in vitro release profile where not more than about 30% of the active ingredient was released by 1 hour after initiation of the experiment, about 35% to 55% of the active ingredient was released by 6 hours, not more than 80% of the active ingredient was released by 12 hours, and not less than 80% of the active ingredient was released by 24 hours.
  • [0054]
    In addition, the formulation was tested in vivo. The pharmacokinetics of this formulation were compared with those of the commercial products Trittico® AC 150 mg CR tablets given BID, and Desyrel® 100 mg IR tablets given TID in a human randomized pharmacokinetic crossover study. It was found that following administration of Formulation 1, trazodone plasma concentrations increased more gradually and peak trazodone plasma concentrations were lower than those of either of the reference products. The mean plasma trazodone concentration measured in 18 patients is shown in FIG. 2. The results indicate that this formulation provides a therapeutic plasma concentration within about 1 hour and provides a substantially constant trazodone concentration from 1 hour to 24 hours. The trazodone plasma concentrations at 24 hours were similar to those following TID administration of Desyrel® and BID administration of Trittico® AC.
  • [0055]
    The in vivo experiments demonstrate that following oral administration of Formulation 1, after a short period to reach acceptable plasma concentrations, trazodone plasma concentrations were maintained at a relatively constant level from approximately 1 hour post-administration to at least 24 hours post-administration.
  • Example 2
  • [0056]
    A second sustained release 300 mg trazodone containing formulation (denoted Formulation 2) was prepared having the composition set forth in TABLE 2.
  • [0000]
    TABLE 2
    Formulation 2
    Tablet Tablet
    Ingredients (mg) %
    CONTRAMID ® excipient 169 24.1
    Trazodone HCl 300 24.1
    Hydroxypropylmethyl cellulose K110M 105 15.0
    Alginic acid 105 15.0
    Cetylpyridinium chloride 7 1.0
    Colloidal silicon dioxide 3.5 0.5
    Sodium stearyl fumarate 10.5 1.5
    Total 700 10
  • [0057]
    The in vitro release kinetics of Formulation 2 were measured using the U.S.P. paddle method as described in Example 1. The in vitro dissolution profile (FIG. 3) shows that in this formulation, not more than about 30% of the active ingredient was released by 1 hour after initiation of the experiment, about 35% to 55% of the active ingredient was released by 6 hours, not more than 80% of the active ingredient was released by 12 hours, and not less than 80% of the active ingredient was released by 24 hours
  • [0058]
    Formulation 2 was also evaluated in vivo. The results obtained were substantially the same when Formulation 2 was compared with Trittico® AC and Desyrel®. The mean plasma trazodone concentration measured in 19 patients is shown in FIG. 4. It was found that following administration of Formulation 2, trazodone plasma concentrations increased to provide a therapeutic concentration in about 1 hour. The plasma concentrations increased till about 6 hours after oral administration but then gradually declined. The plasma concentration of trazodone provided by Formulation 1 was more stable between 1 hours and 24 hours than that provided by Formulation 2.
  • Example 3
  • [0059]
    A first sustained release 150 mg trazodone containing formulation (denoted Formulation 3) was prepared having the composition set forth in TABLE 3.
  • [0000]
    TABLE 3
    Formulation 3
    Tablet Tablet
    Ingredients (mg) %
    CONTRAMID ® excipient 252 46.8
    Trazodone HCl 150 27.8
    Hydroxypropylmethylcellulose K100M 126 23.4
    Colloidal silicon dioxide 3 0.5
    Sodium stearyl fumarate 8 1.5
    Total 540 100
  • [0060]
    The in vitro release kinetics of Formulation 3 were measured using the U.S.P. paddle method as described in Example 1. The in vitro dissolution profile (FIG. 5) shows that in this formulation, not more than about 30% of the active ingredient was released by 1 hour after initiation of the experiment, about 40% to 60% of the active ingredient was released by 6 hours, not more than 80% of the active ingredient was released by 12 hours, and not less than 80% of the active ingredient was released by 24 hours.
  • [0061]
    Formulation 2 was also evaluated in vivo. The mean plasma trazodone concentration measured in 18 patients is shown in FIG. 6. It was found that following administration of Formulation 3, trazodone plasma concentrations increased rapidly to provide a therapeutic concentration in about 1 hour. The results indicate a substantially constant trazodone concentration from 1 hour to 24 hours. As with formulation 1, this appears to show zero order release kinetics between 1 hour and 24 hours following oral administration.
  • INCORPORATION BY REFERENCE
  • [0062]
    The entire disclosure of each of the documents referred to herein is incorporated by reference for all purposes.
  • EQUIVALENTS
  • [0063]
    Although the present invention has been illustrated by means of preferred embodiments thereof, it is understood that the invention intends to cover broad aspects thereof without departing from the spirit and scope of the invention as defined in the appended claims.

Claims (30)

1. A sustained release pharmaceutical composition for once a day oral administration, the composition comprising: about 15% to about 60% by weight trazodone or a derivative thereof, and about 20% to about 50% by weight of cross-linked high amylose starch, wherein the composition, when administered to a mammal, releases the trazodone or derivative thereof so as to maintain a substantially constant effective plasma concentration between about 50 ng/mL and about 3000 ng/mL from at least about one hour to at least about 24 hours after initial administration.
2.-3. (canceled)
4. The sustained release pharmaceutical composition according to claim 1, wherein the composition comprises trazodone hydrochloride.
5. (canceled)
6. The sustained release pharmaceutical composition according to claim 1, wherein the composition comprises 150 mg of trazodone hydrochloride.
7. The sustained release pharmaceutical composition according to claim 6, wherein the plasma trazodone concentration achieved one hour after ingestion is between about 150 ng/mL and about 500 ng/mL.
8. The sustained release pharmaceutical composition according to claim 1, wherein the composition comprises 300 mg of trazodone hydrochloride.
9. The sustained release pharmaceutical composition according to claim 8, wherein the plasma trazodone concentration one hour after ingestion is between about 300 ng/mL and about 1000 ng/mL.
10. The sustained release pharmaceutical composition according to claim 1, wherein the composition comprises from about 20% to about 50% by weight trazodone or trazodone derivative and from about 20% to about 50% by weight percent of cross-linked high amylose starch.
11. The sustained release pharmaceutical composition according to claim 10, wherein the composition comprises from about 35% to 50% by weight percent trazodone or trazodone derivative and from about 15% to 50% by weight of cross-linked high amylose starch.
12. (canceled)
13. The sustained release pharmaceutical composition according to claim 12, wherein the cross-linked high amylose starch comprises between about 65% and 75% by weight amylose and is cross-linked with phosphorus oxychloride.
14. The sustained release pharmaceutical composition according to claim 13, wherein the cross-linked high amylose starch comprises hydroxypropyl side chains.
15. The sustained release pharmaceutical composition according to claim 14, wherein the cross-linked high amylose starch is gelatinized.
16. The sustained release pharmaceutical composition according to claim 1, wherein the composition further comprises a pharmaceutical additive.
17. The sustained release pharmaceutical composition according to claim 16, wherein the pharmaceutical additive is selected from a binding agent, a solubilizing agent, an acidifying agent, a pore forming agent, a lubricant, and a glidant.
18. The sustained release pharmaceutical composition according to claim 17, wherein the binding agent comprises hydroxypropylmethylcellulose.
19. The sustained release pharmaceutical composition according to claim 17, wherein the solubilizing agent is selected from povidone or cetylpyridinium chloride.
20. The sustained release pharmaceutical composition according to claim 17, wherein the acidifying agent comprises alginic acid.
21. The sustained release pharmaceutical composition according to claim 17, wherein the pore forming agent comprises sucrose.
22. The sustained release pharmaceutical composition according to claim 17, wherein the lubricant comprises sodium stearyl fumarate.
23. The sustained release pharmaceutical composition according to claim 17, wherein the glidant comprises colloidal silicon dioxide.
24. The sustained release pharmaceutical composition according to claim 1, wherein the mammal is a human.
25. (canceled)
26. The sustained release pharmaceutical composition according to claim 1, wherein the composition is in the form of a tablet.
27. The sustained release pharmaceutical composition according to claim 26, wherein the tablet is shaped in the form of a caplet.
28. The sustained release pharmaceutical composition according to claim 27, wherein the caplet comprises about 300 mg trazodone.
29.-36. (canceled)
37. A method of treating depression comprising administering once a day to a person with depression a sustained release pharmaceutical composition according to claim 1.
38.-42. (canceled)
US12892466 2005-09-09 2010-09-28 Trazodone Composition for Once a Day Administration Abandoned US20110015205A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US71516205 true 2005-09-09 2005-09-09
US11519194 US7829120B2 (en) 2005-09-09 2006-09-11 Trazodone composition for once a day administration
US12892466 US20110015205A1 (en) 2005-09-09 2010-09-28 Trazodone Composition for Once a Day Administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12892466 US20110015205A1 (en) 2005-09-09 2010-09-28 Trazodone Composition for Once a Day Administration

Publications (1)

Publication Number Publication Date
US20110015205A1 true true US20110015205A1 (en) 2011-01-20

Family

ID=37968167

Family Applications (8)

Application Number Title Priority Date Filing Date
US11519189 Active 2030-08-01 US8795723B2 (en) 2005-09-09 2006-09-11 Sustained drug release compositions
US11519194 Active 2027-03-27 US7829120B2 (en) 2005-09-09 2006-09-11 Trazodone composition for once a day administration
US12892466 Abandoned US20110015205A1 (en) 2005-09-09 2010-09-28 Trazodone Composition for Once a Day Administration
US12892454 Active 2029-06-06 US9439866B2 (en) 2005-09-09 2010-09-28 Trazodone composition for once a day administration
US12905577 Active 2026-09-21 US8962019B2 (en) 2005-09-09 2010-10-15 Sustained drug release composition
US12905567 Active 2026-10-09 US8414919B2 (en) 2005-09-09 2010-10-15 Sustained drug release composition
US14628971 Abandoned US20150306041A1 (en) 2005-09-09 2015-02-23 Sustained drug release composition
US15093468 Pending US20160361262A1 (en) 2005-09-09 2016-04-07 Sustained drug release composition

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11519189 Active 2030-08-01 US8795723B2 (en) 2005-09-09 2006-09-11 Sustained drug release compositions
US11519194 Active 2027-03-27 US7829120B2 (en) 2005-09-09 2006-09-11 Trazodone composition for once a day administration

Family Applications After (5)

Application Number Title Priority Date Filing Date
US12892454 Active 2029-06-06 US9439866B2 (en) 2005-09-09 2010-09-28 Trazodone composition for once a day administration
US12905577 Active 2026-09-21 US8962019B2 (en) 2005-09-09 2010-10-15 Sustained drug release composition
US12905567 Active 2026-10-09 US8414919B2 (en) 2005-09-09 2010-10-15 Sustained drug release composition
US14628971 Abandoned US20150306041A1 (en) 2005-09-09 2015-02-23 Sustained drug release composition
US15093468 Pending US20160361262A1 (en) 2005-09-09 2016-04-07 Sustained drug release composition

Country Status (10)

Country Link
US (8) US8795723B2 (en)
JP (3) JP2009507047A (en)
KR (2) KR101655455B1 (en)
CN (2) CN101242856A (en)
CA (2) CA2616204C (en)
DK (2) DK1931346T3 (en)
EP (2) EP1931346B1 (en)
ES (2) ES2620293T3 (en)
RU (1) RU2008113439A (en)
WO (2) WO2007048219A3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070128269A1 (en) * 2005-09-09 2007-06-07 Sonia Gervais Sustained drug release compositions

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
DE60320039D1 (en) * 2002-10-25 2008-05-08 Labopharm Inc Tramadol formulations with delayed release and 24-hours-effectiveness
CA2533150C (en) * 2003-07-25 2013-03-12 Warner Chilcott Company, Inc. A doxycycline metal complex in a solid dosage form
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
CA2595481C (en) * 2005-01-21 2014-05-13 Warner Chilcott Company, Inc. A tetracycline metal complex in a solid dosage form
DK2178850T3 (en) * 2007-08-03 2014-11-17 Acraf Trazodone and trazodonhydroklorid in purified form
WO2009023672A3 (en) * 2007-08-13 2009-12-30 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
CA2678092C (en) * 2007-10-16 2013-07-30 Labopharm Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
RU2010129907A (en) 2007-12-17 2012-01-27 Лабофарм Инк. (CA) Pharmaceutical form with controlled release, preventing the misuse of
FR2928836B1 (en) * 2008-03-21 2011-08-26 Servier Lab DOSAGE FORM Scored a modified release of the active ingredient
KR101631140B1 (en) * 2008-10-27 2016-06-20 알자 코퍼레이션 Extended release oral acetaminophen/tramadol dosage form
EP2367541B1 (en) 2008-12-16 2014-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
CA2981830A1 (en) * 2008-12-22 2010-07-01 Novartis Ag Dosage regimen of an s1p receptor agonist
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
US20120244362A1 (en) 2011-03-22 2012-09-27 Pramanik Pranabes K Multi-layer sheet structure
CN102935074B (en) * 2011-08-15 2015-04-22 成都康弘药业集团股份有限公司 Trazodone hydrochloride osmotic pump controlled release tablet
CA2877774C (en) 2012-07-12 2017-07-18 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
CA2901802A1 (en) * 2013-03-15 2014-09-25 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
WO2014167440A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of cyclobenzaprine or salts thereof
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
CN104784738B (en) * 2015-04-03 2016-12-07 四川大学 A natural release medical sponge pleiotropic

Citations (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
US3381009A (en) * 1965-12-15 1968-04-30 Acraf Triazole-(4,3-a)-pyridines
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4595587A (en) * 1983-04-18 1986-06-17 Boehringer Ingelheim Kg Divisible pharmaceutical tablet with delayed active ingredient release
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US4824677A (en) * 1986-12-18 1989-04-25 The Unjohn Company Grooved tablet for fractional dosing of sustained release medication
US4906632A (en) * 1987-12-02 1990-03-06 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S Method of preventing myocardial infarction and acute cerebral ischaemia
US4938968A (en) * 1988-07-26 1990-07-03 Norjec Development Associates, Inc. Controlled release indomethacin
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5132116A (en) * 1987-07-16 1992-07-21 Pierre Fabre Medicament Tablets of the hydrophilic matrix type based on salbutamol and a process for their preparation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5336691A (en) * 1991-09-06 1994-08-09 Mcneilab, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5414129A (en) * 1992-09-08 1995-05-09 Chemagis, Ltd. Process for the purification of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol and its salts
US5427799A (en) * 1992-03-25 1995-06-27 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5520931A (en) * 1992-07-29 1996-05-28 Gacell Laboratories Ab Controlled release morphine preparation
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US5595762A (en) * 1992-11-30 1997-01-21 Laboratoires Virbac Stabilized pulverulent active agents, compositions containing them, process for obtaining them and their applications
US5601842A (en) * 1993-09-03 1997-02-11 Gruenenthal Gmbh Sustained release drug formulation containing a tramadol salt
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
US5639476A (en) * 1992-01-27 1997-06-17 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US5776492A (en) * 1995-08-19 1998-07-07 Gruenenthal Gmbh Rapidly disintegrating medicinal form of tramadol or a tramadol salt
US5780057A (en) * 1996-02-19 1998-07-14 Jagotec Ag Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
US5874620A (en) * 1996-08-22 1999-02-23 Chemagis, Ltd. Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride
US5877351A (en) * 1997-12-24 1999-03-02 Wyckoff Chemical Company, Inc. Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its salts
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5885615A (en) * 1996-04-10 1999-03-23 Labopharm Inc. Pharmaceutical controlled release tablets containing a carrier made of cross-linked amylose and hydroxypropylmethylcellulose
US5888545A (en) * 1994-07-01 1999-03-30 Arzneimittelwerk Dresden Gmbh Carbamazepine medicament with retarded active substance release
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US6190591B1 (en) * 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US6211229B1 (en) * 2000-02-17 2001-04-03 Neil B. Kavey Treatment of transient and short term insomnia
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US6245356B1 (en) * 1993-09-09 2001-06-12 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems-amorphous drugs
US6245387B1 (en) * 1998-11-03 2001-06-12 Diamon-Fusion International, Inc. Capped silicone film and method of manufacture thereof
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6254881B1 (en) * 1996-12-18 2001-07-03 Bimeda Research & Development Limited Antiinfective free intramammary veterinary composition
US6261599B1 (en) * 1994-11-04 2001-07-17 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
US20020008133A1 (en) * 2000-06-14 2002-01-24 Katsuhiro Imasaki Two-layer clad pipe and method for making the same
US20020012701A1 (en) * 2000-06-19 2002-01-31 Karl Kolter Process for producing solid oral dosage forms with sustained release of active ingredient
US20020032239A1 (en) * 2000-02-21 2002-03-14 Gruenenthal Gmbh Use of O-desmethyl-N-mono-desmethyl-tramadol
US6372255B1 (en) * 1997-12-23 2002-04-16 Merck Patent Gesellschaft Tablet for instant and prolonged release of one or more active substances
US20020044966A1 (en) * 1999-01-18 2002-04-18 Johannes Bartholomaeus Pharmaceutical formulations containing an opioid and an alpha-agonist
US20020052411A1 (en) * 1998-09-03 2002-05-02 Dagmar Gobel Valproate compositions and processes for making
US6399096B1 (en) * 1995-09-22 2002-06-04 Euro-Celtique S.A. Pharmaceutical formulation
US6419957B1 (en) * 1998-02-24 2002-07-16 Labopharm, Inc. Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents
US20030021846A1 (en) * 2000-03-27 2003-01-30 Karl Kolter Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production
US20030035837A1 (en) * 1993-11-23 2003-02-20 Sackler Richard S. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20030035835A1 (en) * 1999-08-31 2003-02-20 Johannes Bartholomaeus Sustained-release form of administration containing tramadol saccharinate
US20030044464A1 (en) * 1999-08-31 2003-03-06 Iris Ziegler Sustained-release, oral pharamaceutical forms of formulation
US20030054032A1 (en) * 1991-12-24 2003-03-20 Benjamin Oshlack Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US20030068371A1 (en) * 2001-08-06 2003-04-10 Benjamin Oshlack Pharmaceutical formulation containing opioid agonist,opioid antagonist and gelling agent
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030069314A1 (en) * 1999-10-05 2003-04-10 Gruenenthal Gmbh Use of (+)-tramadol, O-demethyltramadol or (+)-O-demethyl-tramadol, O-desmethyl-N-mono-desmethyl-tramadol or (+)- O-desmethyl-N-mono-desmethyltramadol for the treatment of urinary incontinence
US6558701B2 (en) * 1999-06-17 2003-05-06 Gruenenthal Gmbh Multilayer tablet for administering a fixed combination of tramadol and diclofenac
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US6572885B2 (en) * 1991-12-24 2003-06-03 Euro-Celtique, S.A. Orally administrable opioid formulations having extended duration of effect
US20030104061A1 (en) * 1999-01-18 2003-06-05 Gruenenthal Gmbh Controlled release tramadol preparations with a storage-stable release profile and process for their production
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US20030143270A1 (en) * 2001-04-11 2003-07-31 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
US6685964B1 (en) * 1999-01-18 2004-02-03 Gruenenthal Gmbh Opioid analgesics with controlled active substance release
US6723343B2 (en) * 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
US6733783B2 (en) * 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20040131671A1 (en) * 2002-09-21 2004-07-08 Shuyi Zhang Sustained release formulations containing acetaminophen and tramadol
US20040136924A1 (en) * 2002-12-30 2004-07-15 Boyd Thomas J. Oral care compositions and methods
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US20050157382A1 (en) * 2004-01-07 2005-07-21 Kafka James D. Industrial directly diode-pumped ultrafast amplifier system
EP1576986A2 (en) * 2003-10-10 2005-09-21 Labopharm Inc. Sustained-release tramadol formulations with 24-hour clinical efficacy
US20060009465A1 (en) * 2002-01-18 2006-01-12 Dale Edgar Treatment of sleep disorders using sleep target modulators
US20060111307A1 (en) * 2004-11-16 2006-05-25 Wendye Robbins Methods and compositions for treating pain
US20060115530A1 (en) * 2002-10-16 2006-06-01 Anders Pettersson Gastric acid secretion inhibiting composition
US20070003618A1 (en) * 2002-10-25 2007-01-04 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour efficacy
US20070048376A1 (en) * 2005-08-24 2007-03-01 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
US20070128269A1 (en) * 2005-09-09 2007-06-07 Sonia Gervais Sustained drug release compositions

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US338109A (en) * 1886-03-16 Clothes-fork
GB1368574A (en) * 1971-02-12 1974-10-02 Ives Lab Inc Divisible tablet
US4131675A (en) 1978-02-09 1978-12-26 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of combinations of L-DOPA with trazodone and L-DOPA with etoperidone in Parkinsonism
US4344554A (en) * 1978-10-02 1982-08-17 Xerox Corporation Stapling apparatus
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4465660A (en) 1981-04-01 1984-08-14 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
USRE39221E1 (en) 1991-09-06 2006-08-01 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and acetaminophen and its use
JPH0719339Y2 (en) 1991-10-07 1995-05-10 東ポリ株式会社 Senkin clothes hanger
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
FR2688422B1 (en) 1992-03-11 1995-03-10 Coletica
DE69302580T2 (en) 1992-07-24 1996-09-26 Labopharm Inc Networked polyhydroxyl-material for enzymatically controlled drug release
US5849240A (en) 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
EP0654263B1 (en) 1993-11-23 2002-01-23 Euro-Celtique S.A. Method for preparing a sustained release composition
DE4315525B4 (en) 1993-05-10 2010-04-15 Euro-Celtique S.A. A pharmaceutical composition
US5560331A (en) 1994-05-10 1996-10-01 Yamaha Hatsudoki Kabushiki Kaisha Cylinder head for engine
ES2124372T5 (en) 1993-07-01 2004-07-16 Euro-Celtique S.A. Sustained release compositions containing morphine.
WO1995006266A1 (en) 1993-08-24 1995-03-02 Akzo Nobel N.V. Ophthalmic lenses
JPH0719339U (en) * 1993-09-07 1995-04-07 武田薬品工業株式会社 Split tablets
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
GB2284760B (en) 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9413951D0 (en) 1994-07-11 1994-08-31 Therapicon Srl A novel drug delivery system
EP0807433A4 (en) * 1994-12-27 2005-12-28 Akzo Nobel Nv Sustained-release preparation
JP4072597B2 (en) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノンN.V. Organon Depot preparation
US5981592A (en) 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US5672755A (en) 1995-12-07 1997-09-30 Chemagis Ltd. Process for the purification of (RR-SS)-2-dimethyl-aminomethyl-1-(3-methoxyphenyl)cyclohexanol and its salts
DE19607296A1 (en) * 1996-02-27 1997-08-28 Kodak Ag Stitching device for fastening stack-shaped sheets
JPH1095801A (en) * 1996-09-24 1998-04-14 Asahi Chem Ind Co Ltd Cellulose powder having high moldability
DE19640062B4 (en) 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Oral preparation containing a swellable matrix in an aqueous medium at least one pharmaceutical active substance
US5807575A (en) 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
DE69826113T2 (en) 1997-03-11 2005-01-20 Arakis Ltd., Saffron Walden R- and S- enantiomeric separate parts dosage forms containing
DE19710008A1 (en) 1997-03-12 1998-09-17 Basf Ag Solid, at least two-phase preparation forms of an opioid sustained release Analgeticums
BE1011045A3 (en) 1997-03-14 1999-04-06 Ucb Sa Pharmaceutical composition for controlled release of active substances.
US6077537A (en) 1997-05-21 2000-06-20 Warner-Lambert Company Non-sedating acrivastine product
WO1999001111A1 (en) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
ES2234139T3 (en) 1997-08-11 2005-06-16 Alza Corporation Dosage form of an active agent suitable for extended release gastroretention.
EP0912020A3 (en) * 1997-10-25 2002-07-03 Alcatel Alsthom Compagnie Generale d'Electricité Decision method with adaptive thresholds
WO1999038504A8 (en) 1998-01-29 2000-06-22 Sepracor Inc Pharmaceutical uses of optically pure (-)-bupropion
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
CA2335986A1 (en) * 1998-06-26 2000-01-06 Simeng Suy Use of tempo and tempo derivatives for inducing cell death
CA2339355A1 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
CA2348907A1 (en) 1998-11-02 2000-05-11 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
EP1135361A1 (en) 1998-12-02 2001-09-26 Darwin Discovery Limited Therapeutic product and its use
US6129205A (en) 1998-12-09 2000-10-10 Ashworth Bros. Inc. Variable loop count conveyor belt
US6498196B1 (en) 1998-12-22 2002-12-24 Edward Roberts Compounds useful in pain management
DE19901683B4 (en) 1999-01-18 2005-07-21 Grünenthal GmbH Analgesic controlled release
US7450229B2 (en) * 1999-01-25 2008-11-11 Amnis Corporation Methods for analyzing inter-cellular phenomena
WO2000044353A1 (en) 1999-01-29 2000-08-03 Losan Pharma Gmbh Pharmaceutical compositions
DE10023699A1 (en) 1999-08-31 2001-04-19 Gruenenthal Gmbh Retarded release tramadol dosage form, useful e.g. for treating pain, coughs or urinary incontinence, comprising tramadol saccharinate in retarding coating, e.g. of poly(meth)acrylate
DE19947747A1 (en) 1999-10-05 2001-04-12 Gruenenthal Gmbh Treatment of urinary incontinence using (+)-tramadol, O-demethyl-tramadol or O-demethyl-N-mono-desmethyl-tramadol, having strong effect on bladder function without side-effects or analgesic action
WO2001045676A3 (en) 1999-12-20 2002-01-03 Cho Wing Kee Philip Extended release oral dosage composition
US6645537B2 (en) 2000-02-18 2003-11-11 Keurig, Incorporated Beverage filter cartridge
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
DE10015479A1 (en) 2000-03-29 2001-10-11 Basf Ag Solid oral dosage forms with delayed release of active ingredient and high mechanical stability
GB0009522D0 (en) 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
ES2228789T3 (en) 2000-09-22 2005-04-16 Smb Technology tramadol oral composition in the form of granules to take once a day.
US20020106408A1 (en) 2000-12-01 2002-08-08 Johnatan Bacon Prolamin-based sustained-release compositions and delayed-onset compositions
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6897205B2 (en) 2001-01-31 2005-05-24 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
US6806293B1 (en) 2001-03-12 2004-10-19 Darley Pharmaceuticals Ltd Use of pheromone compounds having MAP kinase modulating activity
US6659373B1 (en) 2001-05-30 2003-12-09 L. R. Nelson One touch actuated valve
US6968551B2 (en) 2001-06-11 2005-11-22 John Hediger System and user interface for generation and processing of software application installation instructions
CA2466032A1 (en) * 2001-10-29 2003-05-08 Laure Patricia Ouadji Njiki Methods and dosage forms for improving the bioavailability of therapeutic agents
KR100540035B1 (en) 2002-02-01 2005-12-29 주식회사 태평양 Multi-stage oral drug controlled-release system
ES2377729T3 (en) 2002-02-21 2012-03-30 Valeant International (Barbados) Srl Modified release formulations of at least one form of tramadol
KR20050009983A (en) 2002-03-22 2005-01-26 시락 아게 Sustained release formulation of tramadol
WO2003099265A3 (en) * 2002-05-24 2004-03-18 Carl-Fr Coester Pharmaceutical active substance combination and the use thereof
US7562089B2 (en) * 2002-06-26 2009-07-14 Seagate Technology Llc Systems and methods for storing information to allow users to manage files
FR2841717B1 (en) 2002-06-28 2004-09-10 Bouygues Telecom Sa Messages Input Method
KR101120729B1 (en) * 2002-10-25 2012-04-23 라보팜 유럽 리미티드 Controlled-release compositions
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
JP2006507277A (en) 2002-10-25 2006-03-02 ラボファーマ インコーポレイテッド 24 hours effective sustained-release tramadol formulation
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
WO2004082684A1 (en) * 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
WO2006069293A3 (en) 2004-12-22 2006-09-08 Robert S Friedman Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
US20060193911A1 (en) 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co., Controlled release venlafaxine formulations
US20070237816A1 (en) 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief
CA2734075C (en) 2008-08-12 2017-04-18 Inspirion Delivery Technologies, Llc Pharmaceutical compositions configured to deter dosage form splitting
FR2928836B1 (en) 2008-03-21 2011-08-26 Servier Lab DOSAGE FORM Scored a modified release of the active ingredient

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
US3381009A (en) * 1965-12-15 1968-04-30 Acraf Triazole-(4,3-a)-pyridines
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4595587A (en) * 1983-04-18 1986-06-17 Boehringer Ingelheim Kg Divisible pharmaceutical tablet with delayed active ingredient release
US4683131A (en) * 1983-04-18 1987-07-28 Boehringer Ingelheim Kg Divisible pharmaceutical tablet with delayed active ingredient release
US4824677A (en) * 1986-12-18 1989-04-25 The Unjohn Company Grooved tablet for fractional dosing of sustained release medication
US5132116A (en) * 1987-07-16 1992-07-21 Pierre Fabre Medicament Tablets of the hydrophilic matrix type based on salbutamol and a process for their preparation
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US4906632A (en) * 1987-12-02 1990-03-06 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S Method of preventing myocardial infarction and acute cerebral ischaemia
US4938968A (en) * 1988-07-26 1990-07-03 Norjec Development Associates, Inc. Controlled release indomethacin
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5336691A (en) * 1991-09-06 1994-08-09 Mcneilab, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US20030054032A1 (en) * 1991-12-24 2003-03-20 Benjamin Oshlack Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US6572885B2 (en) * 1991-12-24 2003-06-03 Euro-Celtique, S.A. Orally administrable opioid formulations having extended duration of effect
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5639476A (en) * 1992-01-27 1997-06-17 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5427799A (en) * 1992-03-25 1995-06-27 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5520931A (en) * 1992-07-29 1996-05-28 Gacell Laboratories Ab Controlled release morphine preparation
US5414129A (en) * 1992-09-08 1995-05-09 Chemagis, Ltd. Process for the purification of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol and its salts
US5595762A (en) * 1992-11-30 1997-01-21 Laboratoires Virbac Stabilized pulverulent active agents, compositions containing them, process for obtaining them and their applications
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
US7074430B2 (en) * 1993-05-10 2006-07-11 Euro-Celtique S.A. Controlled release tramadol tramadol formulation
US6254887B1 (en) * 1993-05-10 2001-07-03 Euro-Celtique S.A. Controlled release tramadol
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5601842A (en) * 1993-09-03 1997-02-11 Gruenenthal Gmbh Sustained release drug formulation containing a tramadol salt
US6245356B1 (en) * 1993-09-09 2001-06-12 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems-amorphous drugs
US20030035837A1 (en) * 1993-11-23 2003-02-20 Sackler Richard S. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US6387404B2 (en) * 1993-11-23 2002-05-14 Euro-Celtique S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5888545A (en) * 1994-07-01 1999-03-30 Arzneimittelwerk Dresden Gmbh Carbamazepine medicament with retarded active substance release
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6261599B1 (en) * 1994-11-04 2001-07-17 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6743442B2 (en) * 1994-11-04 2004-06-01 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6335033B2 (en) * 1994-11-04 2002-01-01 Euro-Celtique, S.A. Melt-extrusion multiparticulates
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US5776492A (en) * 1995-08-19 1998-07-07 Gruenenthal Gmbh Rapidly disintegrating medicinal form of tramadol or a tramadol salt
US6399096B1 (en) * 1995-09-22 2002-06-04 Euro-Celtique S.A. Pharmaceutical formulation
US5780057A (en) * 1996-02-19 1998-07-14 Jagotec Ag Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US5885615A (en) * 1996-04-10 1999-03-23 Labopharm Inc. Pharmaceutical controlled release tablets containing a carrier made of cross-linked amylose and hydroxypropylmethylcellulose
US5874620A (en) * 1996-08-22 1999-02-23 Chemagis, Ltd. Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride
US6190591B1 (en) * 1996-10-28 2001-02-20 General Mills, Inc. Embedding and encapsulation of controlled release particles
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
US6254881B1 (en) * 1996-12-18 2001-07-03 Bimeda Research & Development Limited Antiinfective free intramammary veterinary composition
US6372255B1 (en) * 1997-12-23 2002-04-16 Merck Patent Gesellschaft Tablet for instant and prolonged release of one or more active substances
US5877351A (en) * 1997-12-24 1999-03-02 Wyckoff Chemical Company, Inc. Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its salts
US6419957B1 (en) * 1998-02-24 2002-07-16 Labopharm, Inc. Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20020052411A1 (en) * 1998-09-03 2002-05-02 Dagmar Gobel Valproate compositions and processes for making
US6245387B1 (en) * 1998-11-03 2001-06-12 Diamon-Fusion International, Inc. Capped silicone film and method of manufacture thereof
US20020044966A1 (en) * 1999-01-18 2002-04-18 Johannes Bartholomaeus Pharmaceutical formulations containing an opioid and an alpha-agonist
US20030104061A1 (en) * 1999-01-18 2003-06-05 Gruenenthal Gmbh Controlled release tramadol preparations with a storage-stable release profile and process for their production
US6685964B1 (en) * 1999-01-18 2004-02-03 Gruenenthal Gmbh Opioid analgesics with controlled active substance release
US6558701B2 (en) * 1999-06-17 2003-05-06 Gruenenthal Gmbh Multilayer tablet for administering a fixed combination of tramadol and diclofenac
US20050003002A1 (en) * 1999-08-31 2005-01-06 Gruenenthal, Gmbh Sustained-release, oral pharmaceutical formulations and methods of making and using same
US20030035835A1 (en) * 1999-08-31 2003-02-20 Johannes Bartholomaeus Sustained-release form of administration containing tramadol saccharinate
US6576260B2 (en) * 1999-08-31 2003-06-10 Gruenenthal Gmbh Sustained-release form of administration containing tramadol saccharinate
US20030044464A1 (en) * 1999-08-31 2003-03-06 Iris Ziegler Sustained-release, oral pharamaceutical forms of formulation
US6723343B2 (en) * 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
US20030069314A1 (en) * 1999-10-05 2003-04-10 Gruenenthal Gmbh Use of (+)-tramadol, O-demethyltramadol or (+)-O-demethyl-tramadol, O-desmethyl-N-mono-desmethyl-tramadol or (+)- O-desmethyl-N-mono-desmethyltramadol for the treatment of urinary incontinence
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
US20020055544A1 (en) * 1999-10-12 2002-05-09 Marc Kamin Analgesic regimen
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6569463B2 (en) * 1999-11-23 2003-05-27 Lipocine, Inc. Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions
US6211229B1 (en) * 2000-02-17 2001-04-03 Neil B. Kavey Treatment of transient and short term insomnia
US20020032239A1 (en) * 2000-02-21 2002-03-14 Gruenenthal Gmbh Use of O-desmethyl-N-mono-desmethyl-tramadol
US6593373B2 (en) * 2000-02-21 2003-07-15 Gruenenthal Gmbh Pharmaceutical compositions of O-desmethyl-N-mono-desmethyl-tramadol
US20030021846A1 (en) * 2000-03-27 2003-01-30 Karl Kolter Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production
US20020008133A1 (en) * 2000-06-14 2002-01-24 Katsuhiro Imasaki Two-layer clad pipe and method for making the same
US20020012701A1 (en) * 2000-06-19 2002-01-31 Karl Kolter Process for producing solid oral dosage forms with sustained release of active ingredient
US6733783B2 (en) * 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20030143270A1 (en) * 2001-04-11 2003-07-31 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
US20030068371A1 (en) * 2001-08-06 2003-04-10 Benjamin Oshlack Pharmaceutical formulation containing opioid agonist,opioid antagonist and gelling agent
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US20060009465A1 (en) * 2002-01-18 2006-01-12 Dale Edgar Treatment of sleep disorders using sleep target modulators
US20040131671A1 (en) * 2002-09-21 2004-07-08 Shuyi Zhang Sustained release formulations containing acetaminophen and tramadol
US20060115530A1 (en) * 2002-10-16 2006-06-01 Anders Pettersson Gastric acid secretion inhibiting composition
US20090047345A9 (en) * 2002-10-25 2009-02-19 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour efficacy
US20070003618A1 (en) * 2002-10-25 2007-01-04 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour efficacy
US20040136924A1 (en) * 2002-12-30 2004-07-15 Boyd Thomas J. Oral care compositions and methods
EP1576986A2 (en) * 2003-10-10 2005-09-21 Labopharm Inc. Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050157382A1 (en) * 2004-01-07 2005-07-21 Kafka James D. Industrial directly diode-pumped ultrafast amplifier system
US20060111307A1 (en) * 2004-11-16 2006-05-25 Wendye Robbins Methods and compositions for treating pain
US20070048376A1 (en) * 2005-08-24 2007-03-01 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
US20070128269A1 (en) * 2005-09-09 2007-06-07 Sonia Gervais Sustained drug release compositions
US20110021535A1 (en) * 2005-09-09 2011-01-27 Sonia Gervais Trazodone Composition for Once a Day Administration
US20110027370A1 (en) * 2005-09-09 2011-02-03 Sonia Gervais Sustained Drug Release Composition
US20110033537A1 (en) * 2005-09-09 2011-02-10 Sonia Gervais Sustained Drug Release Composition

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070128269A1 (en) * 2005-09-09 2007-06-07 Sonia Gervais Sustained drug release compositions
US20110021535A1 (en) * 2005-09-09 2011-01-27 Sonia Gervais Trazodone Composition for Once a Day Administration
US20110027370A1 (en) * 2005-09-09 2011-02-03 Sonia Gervais Sustained Drug Release Composition
US20110033537A1 (en) * 2005-09-09 2011-02-10 Sonia Gervais Sustained Drug Release Composition
US8414919B2 (en) 2005-09-09 2013-04-09 Angelini Labopharm, Llc Sustained drug release composition
US8795723B2 (en) 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
US8962019B2 (en) 2005-09-09 2015-02-24 Angelini Pharma, Inc. Sustained drug release composition
US9439866B2 (en) 2005-09-09 2016-09-13 Angelini Pharma, Inc. Trazodone composition for once a day administration

Also Published As

Publication number Publication date Type
CA2616416A1 (en) 2007-05-03 application
CA2616204A1 (en) 2007-05-03 application
US8962019B2 (en) 2015-02-24 grant
US20150306041A1 (en) 2015-10-29 application
US8795723B2 (en) 2014-08-05 grant
EP1940467A2 (en) 2008-07-09 application
US20110021535A1 (en) 2011-01-27 application
WO2007048220A2 (en) 2007-05-03 application
KR20080047538A (en) 2008-05-29 application
WO2007048219A2 (en) 2007-05-03 application
CN101252932A (en) 2008-08-27 application
CN101252932B (en) 2012-10-03 grant
KR101655455B1 (en) 2016-09-07 grant
RU2008113439A (en) 2009-10-20 application
US20070128269A1 (en) 2007-06-07 application
US20070128275A1 (en) 2007-06-07 application
JP2009507047A (en) 2009-02-19 application
CN101242856A (en) 2008-08-13 application
WO2007048220A3 (en) 2007-08-02 application
ES2620293T3 (en) 2017-06-28 grant
KR20080047539A (en) 2008-05-29 application
US20110027370A1 (en) 2011-02-03 application
EP1931346A2 (en) 2008-06-18 application
US7829120B2 (en) 2010-11-09 grant
ES2389666T3 (en) 2012-10-30 grant
US20160361262A1 (en) 2016-12-15 application
DK1931346T3 (en) 2012-10-22 grant
US20110033537A1 (en) 2011-02-10 application
EP1931346B1 (en) 2012-07-18 grant
EP1940467A4 (en) 2011-07-27 application
CA2616204C (en) 2015-12-01 grant
WO2007048219A3 (en) 2007-07-19 application
EP1931346A4 (en) 2011-07-20 application
DK1940467T3 (en) 2017-02-13 grant
US8414919B2 (en) 2013-04-09 grant
EP1940467B1 (en) 2016-11-02 grant
JP2009507048A (en) 2009-02-19 application
JP2013116917A (en) 2013-06-13 application
US9439866B2 (en) 2016-09-13 grant
JP5269595B2 (en) 2013-08-21 grant

Similar Documents

Publication Publication Date Title
US6010718A (en) Extended release formulations of erythromycin derivatives
US6551616B1 (en) Extended release formulations of erythromycin derivatives
US4556678A (en) Sustained release propranolol tablet
US20080038347A1 (en) Extended release tablet formulations of flibanserin and method for manufacturing the same
US20020081332A1 (en) Controlled release formulation of erythromycin or a derivative thereof
US20050276851A1 (en) Sustained release aminopyridine composition
US20050136107A1 (en) Extended release antibiotic composition
US20080063706A1 (en) Methods and Medicaments for Administration of Ibuprofen
WO2003090720A1 (en) High drug load tablet
US20050147670A1 (en) Oral disintegrating dosage forms
US20060051417A1 (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
US20070043096A1 (en) Unit dose form with ibuprofen-famotidine admixture
US6300336B1 (en) Method of treating or inhibiting functional disturbances or illnesses of the lower intestinal tracts, particularly abdominal visceral pain which accompanies them
WO2005030175A1 (en) Hrt formulations
US20080020040A1 (en) Unit dose form for administration of ibuprofen
US20090186084A1 (en) Form of administration of racecadotril
WO2000010526A2 (en) New oral formulation for 5-ht4 agonists or antagonists
US20070243249A1 (en) Novel formulation of pyridoxal-5'-phosphate and method of preparation
CN101516347A (en) Pharmaceutical formulation comprising metformin and repaglinide
WO2009049405A1 (en) Bilayer composition for the sustained release of acetaminophen and tramadol
WO2010053691A1 (en) Immediate release dosage forms of sodium oxybate
US20040024018A1 (en) Sustained-release preparations of quinolone antibiotics and method for preparation thereof
US20040009971A1 (en) Use of alprazolam in treatment of disorders of the central nervous system
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
WO2008011426A2 (en) Methods and medicaments for administration of ibuprofen

Legal Events

Date Code Title Description
AS Assignment

Owner name: LABOPHARM (BARBADOS) LIMITED, BARBADOS

Free format text: CHANGE OF ASSIGNEE ADDRESS;ASSIGNOR:LABOPHARM (BARBADOS) LIMITED;REEL/FRAME:025460/0750

Effective date: 20100202

Owner name: LABOPHARM INC., QUEBEC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GERVAIS, SONIA;SMITH, DAMON;RAHMOUNI, MILOUD;AND OTHERS;SIGNING DATES FROM 20070227 TO 20070424;REEL/FRAME:025470/0639

Owner name: LABOPHARM (BARBADOS) LIMITED - PARTIAL INTEREST (E

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LABOPHARM INC.;REEL/FRAME:025470/0688

Effective date: 20080208

Owner name: LABOPHARM EUROPE LIMITED - PARTIAL INTEREST (ENTIR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LABOPHARM INC.;REEL/FRAME:025470/0688

Effective date: 20080208

AS Assignment

Owner name: ANGELINI LABOPHARM, LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LABOPHARM INC.;LABOPHARM EUROPE LIMITED;LABOPHARM (BARBADOS) LIMITED;REEL/FRAME:027589/0342

Effective date: 20120120

AS Assignment

Owner name: ANGELINI PHARMA INC., MARYLAND

Free format text: MERGER;ASSIGNOR:ANGELINI LABOPHARM, LLC;REEL/FRAME:031107/0661

Effective date: 20121205